Delivery Order SPE2DB24D2010-SPE2DB24FZRX9
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,044.29, is for the delivery of Multaq 400 mg tablets. The award was made as a Delivery Order under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of Multaq 400 mg tablets. The single-award contract has a ceiling value of $1,529.88 and runs through March 2025. It is a firm fixed-price delivery order contract, with no set-aside designation indicated. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This federal contract award, with a ceiling value of $1,715.27, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,019.92 firm fixed-price delivery order is for the supply of 4568161278 Multaq 400 mg tablets. The contract has an ultimate completion date of May 7, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $21,298.99 firm-fixed-price delivery order is for the supply of Multaq 400 mg tablets. The contract has a period of performance through May 9, 2025 and is not set aside. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Multaq 400 mg tablets. The $31,110.42 firm-fixed-price delivery order has a completion date of February 15, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical...
- This federal contract award, valued at $7,116.37, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of the drug Multaq 400 mg tablets, a cardiovascular medication, with a completion date of September 16, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,785.46, is a Delivery Order for Multaq 400 mg Tablets. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award, valued at $8,354.02, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order contract for the supply of Multaq 400 mg tablets. The contract is a firm fixed-price, non-set-aside award with a performance period ending on April 23, 2025. Amerisourcebergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
- This contract award, with a ceiling value of $5,858.31, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB24FZRX9Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order under DLA's Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The specific contract award is for the delivery of Multaq 400 mg tablets, a medication used in the treatment of certain heart conditions. The contract has a ceiling value of $58,910.50 and a completion date of February 23, 2024. This award was not designated as a set-aside contract. Amerisourcebergen's parent company, Cencora, Inc., also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $58.9k | 2/22/24 |